CRISPR Therapeutics AG (CRSP) Income towards Parent Company (2015 - 2026)

CRISPR Therapeutics AG has disclosed Income towards Parent Company across 12 years of filings, most recently posting -$122.9 million for Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$122.9 million, up 9.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $41.9 million (up 136.64% YoY), and the FY2025 annual result was $28.9 million, down 22.25% from the prior year.
• Income towards Parent Company came in at -$122.9 million for Q1 2026 at CRISPR Therapeutics AG, down from $479.9 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $479.9 million in Q4 2025 to a low of -$208.6 million in Q2 2025.
• The 5-year median for Income towards Parent Company is -$112.2 million (2023), against an average of -$50.6 million.
• Across the five-year window, Income towards Parent Company sank 124.47% in 2022 and soared 311.71% in 2024, its largest moves.
• CRISPR Therapeutics AG's Income towards Parent Company stood at -$110.5 million in 2022, then soared by 180.45% to $88.9 million in 2023, then jumped by 311.71% to $366.1 million in 2024, then surged by 31.07% to $479.9 million in 2025, then tumbled by 125.62% to -$122.9 million in 2026.
• The last three Income towards Parent Company figures came in at -$122.9 million (Q1 2026), $479.9 million (Q4 2025), and -$106.4 million (Q3 2025), per Business Quant data.